Rezafungin

Recommendation Insufficient data
Comments Accumulating data suggest reduced echinocandin exposure in obesity, but evidence for the ideal dose adjustment strategy is limited (Am J Health Syst Pharm 2023;80:503). A sub-analysis of phase 2 trial data (abstract only) suggests dose adjustment in obesity unnecessary (OFID 2020;7(suppl 1):S378-9.
An unhandled error has occurred. Reload 🗙

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please reload the page.